About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 1NCT06005792

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.

Lead sponsor: Xencor, Inc.•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Xencor, Inc.

This is a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study of XmAb27564. It is planned to enroll approximately 48 adult patients with mild-to-severe plaque psoriasis and 80 adult patients with moderate-to-severe atopic dermatitis. All patients will receive a total of 4 doses of study drug or placebo, administered subcutaneously every 2 weeks. A one year, open-label extension is available to qualifying patients.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Exclusion Criteria

•Have active mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis according to study-specific criteria
•Weight between 40 to 150 kg, inclusive
•No topical treatments for psoriasis or atopic dermatitis for 2 weeks before randomization
•No phototherapy for psoriasis for 4 weeks before randomization
•Washout of oral treatments for psoriasis or atopic dermatitis for 4 weeks before randomization
•Washout of biologic treatments for psoriasis or atopic dermatitis for 12 weeks before randomization
•Stated willingness to comply with all study procedures (including skin biopsies) and availability for the duration of the study
•Patients with a history of active asthma within 5 years of screening, except those that have well controlled asthma symptoms at screening visit.
•Patients who have had any prior investigational treatment with IL-2 therapies

Related studies

RECRUITINGPhase 2

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07290569 · Plaque Psoriasis

RECRUITINGPhase 1

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853 · Food Allergy, Loeys-Dietz Syndrome, and more

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549 · Moderate to Severe Plaque Psoriasis

RECRUITINGPhase 2

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075 · Eczema Atopic Dermatitis, Eczema, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 2, 2025Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment23

Start dateOct 2022

Last updatedDec 2, 2025

Condition

Psoriasis Atopic Dermatitis

Locations shown

Unison Clinical Trials

Sherman Oaks, California

Clinical Trials Research Institute

Thousand Oaks, California

Driven Research

Coral Gables, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions